Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, participated in ESMO Congress 2026.
The ESMO Congress 2026 is the annual meeting of the European Society for Medical Oncology. It stands as one of the world’s most influential oncology platforms for presenting pioneering cancer research. The event takes place from October 23 to 27, 2026, in Madrid, Spain, at the IFEMA MADRID convention center, utilizing a highly accessible hybrid (in-person and virtual) format.
Dr. Tolaney shared posts inpired by ESMO 2026 on X:
Sac-TMT vs chemo in mTNBC (≥2chemo/≥1 in MBC)
OS: 14.7 vs 9.9 mo, HR 0.60, p=0.0004 . And please see the simultaneous publication in Annals of Oncology.”
Title: Sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: final overall survival analysis of the Phase III OptiTROP-Breast01
Authors: B. Xu, Y. Yin, Y. Fan, Q. Ouyang, L. Song, X. Wang, W. Li, M. Li, X. Yan, S. Wang, T. Sun, Y. Teng, X. Tang, Z. Tong, Z. Sun, G. Liu, Y. Diao, X. Jin, J. Ge.
“SWITCH trial: ADC switching 25% HR+ 75% TNBC ORR: 0-8.3%, PFS 1.4-3.0 mo.”
“SYS6043: B7H3 ADC with topo1 payload.
HR+ n=84; ORR 53.7% TNBC n=32, ORR 75%.
HER2+ n=23, ORR 69.6%. No clear assoc of B7H3 exp with ORR ILD 1.4%”
“Bulumtatug Fuvedotin: Nectin-4 ADC, MMAE payload, n=60, ORR 30% ,mPFS=3.7mo”
“Wonderful discussion by Sherene Loi.”
“BRIDGET trial beautifully presented by Sarah Sammons. Adding tucatinib to HP after local therapy for isolated intracranial progression improved PFS in HER2+ MBC.”
“IT trastuzumab and pertuzumab for HER2+ LMD (Pts could continue treatment with HER2-directed systemic therapy).”
“DESTINY-Breast09 CNS Analysis. Assessment of pts with BICR-assessed brain mets (treated and asymptomatic or clinically inactive), n=61.
Deeper systemic and CNS response, and higher iORR.”
“Very nice discussion by Antonio Llombart.”
“Beautiful presentation by Paolo Tarantinoon paired pre/post biopsies on ADC Multifactorial resistance mechanisms for ADCs.”
Dr. Tolaney added more images, you can see them in gallery.
You can also read: ESMO 2026 Metastatic Breast Cancer Guideline: Biomarker-Driven Therapy Reshapes Treatment Across Subtypes.
